Epidemiology of Impaired Coagulant Balance in Diabetes - Full Text View

Sponsored by:	National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:	National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:	NCT00005481

Purpose

To determine the nature, extent and molecular mechanisms responsible for impaired fibrinolysis in White, Black, Hispanic and American Indian populations with respect to the presence or absence of diabetes. The overall objective is to determine whether impairments of fibrinolysis underlie subclinical and clinical vascular disease in diabetes in specific populations with and without accelerated microvascular disease.

Condition
Cardiovascular Diseases Heart Diseases Diabetes Mellitus Blood Coagulation Disorders

Genetics Home Reference related topics: hemophilia

MedlinePlus related topics: Bleeding Disorders Diabetes Heart Diseases

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:	September 1996
Estimated Study Completion Date:	July 2002

Detailed Description:

BACKGROUND:

The results of this project should clarify the extent to which results obtained in experimental animals pertain directly to diabetes in human subjects. The study will also assist in the interpretation of results from clinical studies and from platelet activation experiments.

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

No eligibility criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005481

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

Investigator:

Russell Tracy

University of Vermont

More Information

Publications:

Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 1999 Oct;10(5):435-41. Review.

Smiles AM, Macy EM, Sakkinen PA, Bovill EG, Mann KG, Tracy RP. Variability in plasma prothrombin concentration: implications for use in epidemiology. Blood Coagul Fibrinolysis. 1998 Sep;9(6):525-31.

Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002 Apr;51(4):1131-7.

Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost. 2001 Dec;86(6):1495-500.

Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1407-15.

Hanley AJ, Karter AJ, Festa A, D'Agostino R Jr, Wagenknecht LE, Savage P, Tracy RP, Saad MF, Haffner S. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002 Aug;51(8):2642-7.

Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabet Med. 2002 Nov;19(11):939-43.

Festa A, D'Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites. The Insulin Resistance Atherosclerosis Study. Circulation. 2003 Apr 28 [epub ahead of print]

Study ID Numbers:	4965
Study First Received:	May 25, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00005481 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Metabolic Diseases
Hemorrhagic Disorders
Heart Diseases
Hematologic Diseases
Blood Coagulation Disorders
Vascular Diseases

Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Glucose Metabolism Disorders
Hemostatic Disorders
Metabolic Disorder

Additional relevant MeSH terms:

Metabolic Diseases
Hemorrhagic Disorders
Heart Diseases
Hematologic Diseases
Blood Coagulation Disorders
Vascular Diseases

Diabetes Mellitus
Endocrine System Diseases
Cardiovascular Diseases
Glucose Metabolism Disorders
Hemostatic Disorders

ClinicalTrials.gov processed this record on May 07, 2009